December 23, 2019 09:58 AM ESTUpdated 11:07 AM

Pfizer inks a back-ended $250M deal for skin-targeted JAK, pays $25M to set up the next leg of their hemophilia A R&D journey — while BioMarin jockeys for first OK

→ Pfizer wants to find out a lot more about Theravance’s approach to developing specially targeted JAK inhibitors. The pharma giant is

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfiz­er inks a back-end­ed $250M deal for skin-tar­get­ed JAK, pays $25M to set up the next leg of their he­mo­phil­ia A R&D jour­ney — while Bio­Marin jock­eys for first OK